2 active not recruiting, 1 recruiting. 2 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Active not recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow ADP Ribose Transferases: new trials by email Literature Review of ADP Ribose Transferases trials Research Report on ADP Ribose Transferases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC Low-dose radiotherapy, Etoposide, Cisplatin - Lung Cancer, Extensive-stage Small-cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Sichuan University | 45 | 2024-04-18 | 2026-05-05 |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors Ceralasertib, Olaparib, Durvalumab - Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer | Phase 2 | Active not recruiting | Rahul Aggarwal | 83 | 2019-01-17 | 2026-04-23 |
| Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer [18F]FluorThanatrace, Poly(ADP Ribose) Polymerase 1 - Prostate Cancer | Early Phase 1 | Active not recruiting | Abramson Cancer Center at Penn Medicine | 30 | 2017-07-14 | 2026-02-20 |
Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Small Cell Lung Carcinoma (1)
Abramson Cancer Center at Penn Medicine (1) · Rahul Aggarwal (1) · Sichuan University (1)
United States (2) · China (1)
Dan Pryma, MD (1) · Rahul Aggarwal, MD (1) · You Lu, MD (1)